Premium
Comparative study of therapy‐related and de novo adult b‐cell acute lymphoblastic leukaemia
Author(s) -
Abdel Rahman Zaid H.,
Parrondo Ricardo D.,
Heckman Michael G.,
Wieczorek Mikolaj,
Miller Kevin C.,
Alkhateeb Hassan,
Sproat Lisa Z.,
Murthy Hemant,
Hogan William J.,
KharfanDabaja Mohamed A.,
Peterson Jess F.,
Baughn Linda B.,
Hoppman Nicole,
Litzow Mark R.,
Ketterling Rhett P.,
Greipp Patricia T.,
Foran James M.
Publication year - 2022
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17906
Subject(s) - medicine , minimal residual disease , odds ratio , gastroenterology , cytogenetics , transplantation , acute lymphocytic leukemia , oncology , bone marrow , lymphoblastic leukemia , leukemia , biology , biochemistry , chromosome , gene
Summary We report a comparative analysis of patients with therapy‐related acute lymphoblastic leukaemia (tr‐ALL) vs de novo ALL. We identified 331 patients with B‐ALL; 69 (21%) were classified as tr‐ALL. The most common prior malignancies were breast (23·2%) and plasma cell disorders (20·3%). Patients with tr‐ALL were older (median 63·2 vs. 46·2 years, P < 0.001), more often female (66·7% vs. 43·5%, P < 0·001), and more likely to have hypodiploid cytogenetics (18·8% vs. 5·0%, P < 0·001). In multivariable analysis, patients with tr‐ALL were less likely to achieve complete remission [odds ratio (OR) = 0·16, P < 0·001] and more likely to be minimal residual disease‐positive (OR = 4·86, P = 0·01) but had similar OS after diagnosis and allo‐haematopoietic cell transplantation.